Robert Stefanovich Sells 169,427 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 169,427 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total value of $2,756,577.29. Following the sale, the chief financial officer owned 109,850 shares in the company, valued at $1,787,259.50. The trade was a 60.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 23rd, Robert Stefanovich sold 1,094 shares of CryoPort stock. The stock was sold at an average price of $8.18, for a total value of $8,948.92.
• On Monday, March 16th, Robert Stefanovich sold 2,743 shares of CryoPort stock. The stock was sold at an average price of $8.00, for a total value of $21,944.00.
• On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The stock was sold at an average price of $7.76, for a total value of $300,312.00.

CryoPort Price Performance

Shares of CYRX stock opened at $15.19 on Wednesday. CryoPort, Inc. has a 12-month low of $6.16 and a 12-month high of $16.73. The firm has a market capitalization of $765.58 million, a price-to-earnings ratio of 11.25 and a beta of 1.90. The business has a 50 day simple moving average of $12.04 and a 200 day simple moving average of $10.22.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. On average, equities analysts anticipate that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CYRX shares. Jefferies Financial Group set a $13.50 price target on CryoPort in a research note on Monday. Guggenheim increased their price target on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Needham & Company LLC raised their price objective on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. KeyCorp raised their price objective on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Finally, Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, CryoPort presently has a consensus rating of “Moderate Buy” and an average price target of $15.11.

Institutional Trading of CryoPort

Hedge funds have recently modified their holdings of the business. UBS Group AG lifted its holdings in shares of CryoPort by 6.8% in the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after purchasing an additional 90,363 shares in the last quarter. Mak Capital One LLC purchased a new stake in shares of CryoPort in the third quarter valued at $7,756,000. First Eagle Investment Management LLC purchased a new stake in shares of CryoPort in the fourth quarter valued at $2,996,000. Legato Capital Management LLC purchased a new stake in shares of CryoPort in the fourth quarter valued at $443,000. Finally, Segall Bryant & Hamill LLC purchased a new stake in shares of CryoPort in the third quarter valued at $652,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.